-
Alcaraz exits Shanghai Masters in straight-sets loss
-
UK retains early access to test latest US AI models
-
Pope to enter hospital on Tuesday for lung operation
-
Top NATO commander warns Russia any attack would be 'futile'
-
Renshaw shines again before Australia declaration
-
Stolen Renoir paintings found behind wall in France: prosecutor
-
Atletico's Simeone encourages goalless Alvarez improvement
-
UNHCR sounds alarm on funding crisis
-
FXGLOBE Rebuilds Its Copy Trading and PAMM Business With B2BROKER's B2COPY
-
French supermarket chains say cyberattack forced refrigerator shutdown
-
Nepal rescuers search for missing after flash flood
-
Minister's resignation rocks German coalition
-
Oil rises as Trump comments roil energy markets
-
Hurricane Simon lashes Mexico's Pacific coast, threatens landfall
-
Premier League in limbo as Manchester City soar
-
France schools protest rumbles on as Macron urges 'respect'
-
Zelensky vows to respond as Moscow silent on 'energy ceasefire'
-
Americans Hall and Woodford win economics Nobel for stabilisation models
-
Thousands march in India's capital to demand election chief resign
-
MEXC Brings AI, TradFi and the Future of Trading to Life at TOKEN2049 Singapore
-
African players in Europe: Mbeumo ends goal drought as United draw
-
Italian rice farmer beats heat with biodiversity haven
-
France's high school students plan fresh protests
-
Stocks mixed as oil prices slip after Trump hails 'energy ceasefire'
-
NZ bank in free speech row over 'explicit' sheep memes
-
Opposition, journalists allege police abuses during India protests
-
China Open champ Zheng withdraws from Wuhan citing fatigue
-
DATA Network joins Sui and Walrus to scale the supply chain for AI training data
-
Brewers edge Dodgers 2-1 in National League Championship Series opener
-
Melbourne man linked to suspected flydubai hijacker condemns 'false accusations'
-
Pope to have surgery to remove lung nodule
-
North Korea fires 'several ballistic missiles' into Sea of Japan
-
Stocks rise as oil prices tumble after Trump hails 'energy ceasefire'
-
El Nino sets temperature record in key Pacific zone: EU monitor
-
Man City charges cloud hangs over Premier League season
-
Nature does not respect borders: UN biodiversity chief
-
Top NATO commander set to issue warning to Russia over any attack
-
World leaders urged to 'course correct' as UN nature goals fall short
-
Software, sprints, trolls: Singapore Grand Prix talking points
-
New York's notorious Rikers jail awaits elusive closure
-
Riyadh airport hit by fresh Houthi strike day after deadly attack
-
Unbeaten 49ers edge Seahawks while Vikings stay perfect
-
Great Western Mining Corporation PLC Announces Exercise of Warrants and Issue of Equity
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 12
-
Yokogawa Brings Publication-Backed Validation from More Than 60,000 Scientific Publications to Its CSU Spinning Disk Confocal Systems with Bioz
-
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
-
U.S. Energy Secretary Chris Wright, EXIM Chairman John Jovanovic, Nebraska Governor Jim Pillen, Senators Deb Fischer and Pete Ricketts, and Congressman Adrian Smith to Visit NioCorp's Critical Minerals Mine Site
-
Ondas Announces Regna AI, Powered by Palantir, to Advance Sovereign AI
-
Brightline Interactive to Attend the 2026 Maxim Growth Summit
-
Cytta Air's Market-Ready IGAN(TM) (Incident Global Area Network) Platform Receives Outstanding Police Department Feedback
Verseon Chooses DataKrypto's FHEnom for AI(TM) to Ensure Continuous Encryption of AI-Driven Medical Research and Clinical Trial Data
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
BURLINGAME, CA / ACCESS Newswire / October 1, 2025 / DataKrypto, the creator of the fastest fully homomorphic encryption (FHE) solutions on the market, announced today that Verseon, a drug development innovator, is deploying its cutting-edge FHEnom for AI to ensure the continuous security of AI datasets and proprietary models.
Verseon's team of scientists, biologists, and medical researchers works diligently to create medicines that improve the world's treatment of all major human diseases. AI plays a vital role in Verseon's drug development and clinical trials, and ensuring that highly sensitive data is always protected, throughout AI training and inference, is crucial for maintaining compliance with stringent data privacy regulations.

"DataKrypto's FHEnom for AI gives us a secure, continuously encrypted solution for our AI training, fine-tuning, and real-world usage," said David Kita, CSO of Verseon. "With implementation taking just hours, the solution combines security with convenience and speed, allowing us to focus on our core activities."
"Verseon's mission-critical drug discovery and development work is reliant on its ability to maintain continuous protection of its clinical trial data and proprietary AI models," said Ravi Srivatsav, CEO of DataKrypto. "FHEnom for AI fills the encryption gap by enabling AI training and processing without having to decrypt data, which potentially exposes it to malicious use. We are proud to provide the first solution that gives companies like Verseon confidence and peace of mind with their AI implementations, knowing that their data is always secure."
Building Trust in AI with DataKrypto
FHEnom for AI is an AI-compliant, zero-knowledge framework that safeguards both customized open-source AI models (adapted for specific enterprise needs) and proprietary models, while ensuring the privacy and protection of sensitive data. It defends against malicious activities, misuse, and adversarial manipulation, securing intellectual property and maintaining the confidentiality of critical datasets. DataKrypto's solution helps companies deploying AI overcome concerns about data privacy and model security.
For more information about FHEnom for AI, visit https://datakrypto.com/products/.
About Verseon
Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company's drug programs features multiple novel candidates with unique therapeutic properties. Other current methods can find none of these candidates. Verseon's rapidly growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancer. The company's supporters and advisors include multiple Nobel laureates, former heads of R&D at major pharmaceutical companies, and various key opinion leaders in the field of medicine.
About DataKrypto
DataKrypto reimagines AI security for the enterprise. By combining FHEnom™-the fastest, most scalable Fully Homomorphic Encryption technology available-with Trusted Execution Environments (TEEs), DataKrypto enables organizations to adopt, create, and use AI tools with unmatched security and performance. Every model, every dataset-always encrypted. Even the largest AI systems run securely, with performance intact. DataKrypto empowers organizations to embrace AI, ensuring protection at every step. Learn more at www.datakrypto.com.
Media Contact:
Liz Youngs
Trier and Company for DataKrypto
1-843-412-6327
[email protected]
SOURCE: DataKrypto
View the original press release on ACCESS Newswire
R.Garcia--AT